Assessment of ventricular remodeling in heart failure clinical trials

Current Heart Failure Reports

Volumn 9, Issue 4, 2012, Pages 328-336

  Kirkpatrick, James N ^a   Sutton, Martin St John ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cardiac imaging; Clinical trials; Heart failure; Left ventricular remodeling

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARDIAC GLYCOSIDE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; IONOTROPIC RECEPTOR AGONIST; ISOSORBIDE DINITRATE; METOPROLOL; NITRATE; PRAZOSIN; SPIRONOLACTONE;

ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CONGESTIVE HEART FAILURE; EPICARDIUM; HEART FAILURE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE REMODELING; HEART VENTRICLE WALL; HORMONAL REGULATION; HUMAN; HYPERKALEMIA; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; PROGNOSIS; TISSUE REGENERATION; VASODILATATION; WALL STRESS;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOTONIC AGENTS; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; VASODILATOR AGENTS; VENTRICULAR REMODELING;

EID: 84872267972     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-012-0116-6     Document Type: Article

References (67)

1. Heyndrickx GR, Amano J, Patrick TA, Manders WT, et al. Effects of coronary reperfusion on regional coronary blood flow and function. Circulation. 1985;71:1029-37.
2. Gaudron P, Eilles C, Kugler I, Ertl G. Progressive left ventricular dysfunction and remodeling after myocardial function. Circulation. 1993;87:755-63.
3. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation. 1990;81:1161-72.
4. Erlebacher JA, Weiss JL, Eaton LW, Kallman C, et al. Late effects of acute infarct dilation on heart size: a two dimensional echocardiographic study. Am J Cardiol. 1982;49:1120.
5. Jackson BM, Gorman JH IIISalgo IS, St John Sutton M, Edmunds Jr LH. Increased wall stress due to altered borderzone geometry as assessed by perfusion echocardiography. Am J Physiol. 2003;284: H475-9.
6. Mitchell GR, Lamas GA, Vaughan DE, Pfeffer MA. Left ventricular remodeling in the year after anterior myocardial infarction: a quantitative analysis of contractile segment lengths and ventricular shape. J Am Coll Cardiol. 1992;19:1136-44.
7. Ross RS, Borg TK. Integrins and the myocardium. Circ Res. 2001;88:1112-9. (Pubitemid 34132510)
8. Bozurt B, Kribbs SB, Clubb FJ, Michael LH, et al. Pathophysologically relevant concentrations of tumor necrosis factor α promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97:1382-91.
9. Mann DL. Inflammatory mediators and the failing heart: passed, present and the forseeable future. Circ Res. 2002;91:988-98.
10. Spinale FG. Matrix Metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002;90:520-30.
11. Weber KT. Extracellular matrix remodeling in heart failure. A role for de novo angiotensin II generation. Circulation. 1997;96:4065-82.
12. The Digitalis Investigative Group (DIG). The effects of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-33.
13. Cohn JN, Archibald DG, Ziesche S, Fransciosa JA, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med. 1986;314:1547-52.
14. Cohn JN, Johnson G, Ziesche S, Cobb F, et al. A comparison of enalapril with hydralazine and isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-10.
15. Power JM, Raman J, Dornom A, Farish SJ, et al. Passive ventricular constraint amends the course of heart failure: a study in an ovine model of dilated cardiomyopathy. Cardiovasc Res. 1999;44:549-55.
16. Starling RH, Jessup M, Oh JK, Sabbah HN, et al. Sustained benefits of the CorCap support device on left ventricular remodeling: three year follow up results from the Acorn clinical trial. Ann Thorac Surg. 2007;84:1236-42.
17. Sharpe N. Pharmacologic effects on cardiac remodeling. Curr Heart Fail Rep. 2004;1:9-13.
18. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-Term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 1989;79:483-90.
19. Hall JA, Kaumann AJ, Brown MJ. Selective beta-1 adrenoceptor blockade enhances positive inotropic responses to endogenous catecholamines mediated through beta-2 adrenoceptors in human atrial myocardium. Circ Res. 1990;66:1610-23.
20. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larabee P, Bristow MR. Comparative hemodynamic, LV functional, and antiadrenergic effects of chronic treatment with metoprolol vs. carvedilol in the failing heart. Circulation. 1996;94:2817-25.
21. Yoshikawa T, Port JD, Asano K, Chidiak P, Bouvier M, Dutcher D, Roden RL, Minobe W, Tremmel KD, Bristow MR. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J. 1996;17:8-16.
22. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A, for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342:1441-6. (Pubitemid 24000287)
23. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the US Carvedilol Heart Failure Study Group. Effect of carvedilol on morbidity and mortality in chronic heart failure. N Engl J Med. 1996;334:1349-55.
24. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial. Circulation. 1996;94:2793-9. (Pubitemid 26411743)
25. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N; MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;1;94(11):2807-16.
26. Doughty RN, Whalley GA, Gamble G, et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease: Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol. 1997;29:1060-6. (Pubitemid 27149582)
27. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385-90.
28. Doughty RN, Whalley GA, Walsh HA, Gamble GD, López-Sendón J, Sharpe N, CAPRICORN Echo Substudy Investigators. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation. 2004;109(2):201-6. (Pubitemid 38114140)
29. Lowes BD, Gill EA, Abraham WT, et al. The effect of carvedilol on the left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol. 1999;83:1201-5. (Pubitemid 29183917)
30. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-7.
31. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial In Congestive Heart Failure (MERIT-HF). JAMA. 2000;283:1295-302.
32. Groenning BA, Nilsson JC, Sondergaard L, Fritz-Hansen T, Larsson HB, Hildebrandt PR. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol. 2000;36(7):2072-80.
33. Remme WJ, Riegger G, Hildebrandt P, et al. The benefits of early combination treatment of carvedilol and an ACEinhibitor in mild heart failure and left ventricular systolic dysfunction. The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial (CARMEN). Cardiovasc Drugs Ther. 2004;18:57-66.
34. Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, Ponikowski P, Skene A, van de Ven L, Verkenne P, Lechat P, CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005;112(16):2426-35. Epub 2005 Sep 4.
35. van de Ven LL, van Veldhuisen DJ, Goulder M, Zilahi Z, Meyer WR, Willenheimer R. The effect of treatment with bisoprolol-first versus enalapril-first on cardiac structure and function in heart failure. Int J Cardiol. 2010;144(1):59-63. This small study addressed the important question of whether initiation of heart failure treatment should begin with ACE-inhibitors first or beta blockers first.
36. Spenser FA, Meyer TE, Gore JM, Goldberg RJ, et al. Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure, the National Registry for Myocardial Infarction. Circulation. 2002;105:2605-10.
37. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL. Valsartan in Acute Myocardial Infarction trial Investigators (VALIANT). N Engl J Med. 2003;349:1893-906.
38. Ky B, Plappert T, Kirkpatrick JN, Silvestry FE, et al. Left ventricular remodeling in human heart failure, Quantitative echocardiographic assessment of 1794 patients. Echocardiography. 2012;29 (7):758-65.
39. Pfeffer MA, Braunwald E, Moye LA, Basta L, et al. On behalf of the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327:669-77.
40. St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, et al. Quantitative two dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction: the protective effects of captopril. Circulation. 1994;89:68-75.
41. St John Sutton M, Lee D, Rouleau JL, et al. Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation. 2003;107:2577-82.
42. SOLVD Investigators. Effects of enalopril on the development of heart failure in asymptomatic patients with reduced ejection fraction. N Engl J Med. 1992;327:685-91.
43. SOLVD Investigators. Effect of enalapril onsurvival in patients with reduced ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
44. The Acute Infarction Ramipril Efficacy (AIRE) study investigators. The effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-8.
45. Ambrosioni E, Borghi C. Magnani for the Survival of Myocardial Infarction Long term Evaluation (SMILE) study investigators. The effect of the angiotensin converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 1995;332(2):80-5.
46. The International Collaborative Study Group. Reduction of infarct size with the early use of timolol in acute myocardial infarction. N Engl J Med. 1984;310:9-16.
47. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction. Lancet. 1986;2:57-66.
48. Pitt B, Zannad F, Remme WJ, Cody R, et al. The effect of spironolactone on mortality and morbidity in patients with severe heart failure. N Engl J Med. 1999;341:709-17.
49. Pitt B, Remme WJ, Zannad F, Neaton J, et al. Eplerinone post AMI heart failure efficacy and survival study: primary results of the EPHESUS trial. N Engl J Med. 2003;348:1309-21.
50. Mohri S, He K-L, Dickstein M, Mika Y, et al. Cardiac contractility modulation by electric currents applied during the refractory periods. Am J Physiol. 2002;282:H642-7.
51. Yu CM, Chan JY, Zhang Q, Yip EW, et al. Impact of cardiac contractility modulation on left ventricular global and regional function and remodeling. J Am Coll Cardiol Cardiovasc Imaging. 2009;2:1341-9.
52. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients in heart failure and intraventricular delay. N Engl J Med. 2001;344:873-80.
53. Saxon LA, De Marco T, Schafer J, et al. Effects of long-Term biventricular stimulation for resynchronization on echocardiographic measures of remodeling. Circulation. 2002;105:1304-10.
54. Yu CM, Chau E, Sanderson JE, et al. Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation. 2002;105:438-45.
55. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845-53.
56. St John Sutton M, Plappert T, Hilpisch KE, Abraham WT, et al. Sustained Reverse left structural remodeling with cardiac resynchronization at one year is a function of etiology. Circulation. 2006;113:266-72.
57. Chung ES, Leon AR, Tavazzi L, Sun J-P, et al. Results of the predictors of response to CRT (PROSPECT) trial. Circulation. 2008;117:2608-16.
58. Cleland JG, Daubert JC, Erdmann E, Fremantle N, Cardiac resynchronization -heart failure (CARE-HF) study investigators, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-49.
59. Moss AJ, Hall WJ, Cannom DS, Klein H, MADIT-CRT trial investigators, et al. Cardiac resynchronization therapy for the prevention of heart failure events. N Engl J Med. 2009;361:1329-38. The MADIT-CRT trials was one of the larger CRT trials with longterm follow up.
60. Linde C, Abraham WT, Gold MR, St John Sutton M, REVERSE (Resynchronization reverses remodeling in systolic left ventricular dysfunction) study group, et al. Randomized trial of resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008;52:1834-43.
61. Bristow MR, Saxon LA, Boehmer J, Kreuger S, Comparison of medical therapy, pacing and defibrillation in heart failure (COMPANION) investigator, et al. Cardiac resynchronization therapy with and without implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-50.
62. Birks EJ, George RS. Molecular changes occurring during reverse remodelling following left ventricular assist device support. J Cardiovasc Transl Res. 2010 Dec;3(6):635-42. 13
63. Goldstein DJ, Maybaum S, MacGillivray TE, Moore SA, Bogaev R, Farrar DJ, Frazier OH, HeartMate II Clinical Investigators. Young patients with nonischemic cardiomyopathy have higher likelihood of left ventricular recovery during left ventricular assist device support. J Card Fail. 2012;18(5):392-5.
64. Dandel M, Weng Y, Siniawski H, Potapov E, Drews T, Lehmkuhl HB, Knosalla C, Hetzer R. Prediction of cardiac stability after weaning from left ventricular assist devices in patients with idiopathic dilated cardiomyopathy. Circulation. 2008;118:S94-S105.
65. Birks EJ, George RS, Hedger M, Bahrami T, Wilton P, Bowles CT, Webb C, Bougard R, Amrani M, Yacoub MH, Dreyfus G, Khaghani A. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation. 2011;123 (4):381-90.
66. Perin EC, Willerson JT, Pepine CJ, Henry TD, et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA. 2012;307:1717-26. This recent trial examined the effect of autologous bone marrow cells injected into the myocardium on LV function and employed LV volume and LVEF assessments as endpoints.
67. Corsi C, Lang RM, Veronesi F, Weinert L, et al. Volumetric quantification of global and regional left ventricular function from real-Time three-dimensional echocardiographic images. Circulation. 2005;112:1161-70.